Associated Papers
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A et al.
Annals of Hematology, 2015
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.
Breccia M et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2014
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Chan WW et al.
Cancer Cell, 2011
Select a paper to view details